Dyslipidemia, statins and prostate cancer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Dyslipidemia and prostate cancer are two of the most common medical conditions affecting adult males in the USA. In recent years, a large volume of research has focused on investigating the relationship between these two disease processes as well as the effect of the cholesterol-lowering medications, such as 3-hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitors (better known as 'statins), on the development and progression of prostate cancer. While there is a paucity of prospective research, encouraging results have been reported in several retrospective clinical studies. Additionally, basic science research has identified interactions between lipids and prostate cancer cells in several key areas. This article will discuss recent clinical and basic science research examining the relationship between dyslipidemia, statins and prostate cancer.

Original languageEnglish
Pages (from-to)981-990
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume12
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dyslipidemias
Prostatic Neoplasms
Research
Coenzyme A
Hydroxyl Radical
Oxidoreductases
Retrospective Studies
Cholesterol
Lipids

Keywords

  • dyslipidemia
  • HMG-CoA reductase inhibitors
  • metabolic syndrome
  • prostate cancer
  • statins

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Dyslipidemia, statins and prostate cancer. / Rice, Kevin R.; Koch, Michael; Cheng, Liang; Masterson, Timothy.

In: Expert Review of Anticancer Therapy, Vol. 12, No. 7, 07.2012, p. 981-990.

Research output: Contribution to journalArticle

@article{692c518acd2845bba64e663cc1d4558a,
title = "Dyslipidemia, statins and prostate cancer",
abstract = "Dyslipidemia and prostate cancer are two of the most common medical conditions affecting adult males in the USA. In recent years, a large volume of research has focused on investigating the relationship between these two disease processes as well as the effect of the cholesterol-lowering medications, such as 3-hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitors (better known as 'statins), on the development and progression of prostate cancer. While there is a paucity of prospective research, encouraging results have been reported in several retrospective clinical studies. Additionally, basic science research has identified interactions between lipids and prostate cancer cells in several key areas. This article will discuss recent clinical and basic science research examining the relationship between dyslipidemia, statins and prostate cancer.",
keywords = "dyslipidemia, HMG-CoA reductase inhibitors, metabolic syndrome, prostate cancer, statins",
author = "Rice, {Kevin R.} and Michael Koch and Liang Cheng and Timothy Masterson",
year = "2012",
month = "7",
doi = "10.1586/era.12.75",
language = "English",
volume = "12",
pages = "981--990",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Dyslipidemia, statins and prostate cancer

AU - Rice, Kevin R.

AU - Koch, Michael

AU - Cheng, Liang

AU - Masterson, Timothy

PY - 2012/7

Y1 - 2012/7

N2 - Dyslipidemia and prostate cancer are two of the most common medical conditions affecting adult males in the USA. In recent years, a large volume of research has focused on investigating the relationship between these two disease processes as well as the effect of the cholesterol-lowering medications, such as 3-hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitors (better known as 'statins), on the development and progression of prostate cancer. While there is a paucity of prospective research, encouraging results have been reported in several retrospective clinical studies. Additionally, basic science research has identified interactions between lipids and prostate cancer cells in several key areas. This article will discuss recent clinical and basic science research examining the relationship between dyslipidemia, statins and prostate cancer.

AB - Dyslipidemia and prostate cancer are two of the most common medical conditions affecting adult males in the USA. In recent years, a large volume of research has focused on investigating the relationship between these two disease processes as well as the effect of the cholesterol-lowering medications, such as 3-hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitors (better known as 'statins), on the development and progression of prostate cancer. While there is a paucity of prospective research, encouraging results have been reported in several retrospective clinical studies. Additionally, basic science research has identified interactions between lipids and prostate cancer cells in several key areas. This article will discuss recent clinical and basic science research examining the relationship between dyslipidemia, statins and prostate cancer.

KW - dyslipidemia

KW - HMG-CoA reductase inhibitors

KW - metabolic syndrome

KW - prostate cancer

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=84864576472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864576472&partnerID=8YFLogxK

U2 - 10.1586/era.12.75

DO - 10.1586/era.12.75

M3 - Article

C2 - 22845413

AN - SCOPUS:84864576472

VL - 12

SP - 981

EP - 990

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 7

ER -